Literature DB >> 19671788

The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe.

R Cervera1, M-C Boffa, M A Khamashta, G R V Hughes.   

Abstract

The Euro-Phospholipid project started in 1999 with a multicentre, consecutive and prospective design. A total cohort of 1000 patients with antiphospholipid syndrome (APS), derived from 13 countries (Belgium, Bulgaria, Denmark, France, Germany, Greece, Hungary, Israel, Italy, the Netherlands, Portugal, Spain and United Kingdom), has been followed since then. This project allowed the identification of the prevalence and characteristics of the main clinical and immunological manifestations at the onset and during the evolution of APS and demonstrated that it is possible to recognize more homogeneous subsets of clinical significance. Patients with APS associated with systemic lupus erythematosus (SLE) had more episodes of arthritis, livedo reticularis and more frequently exhibited thrombocytopenia and leucopenia. Female patients had more episodes of arthritis and livedo reticularis - both connected with the higher prevalence of migraine and SLE-related APS in women, while male patients had more myocardial infarction, epilepsy and lower limb arterial thrombosis. Childhood onset patients presented more episodes of chorea and jugular vein thrombosis, whereas older onset patients were more frequently male and had more strokes and angina pectoris, but less frequently livedo reticularis.

Entities:  

Mesh:

Year:  2009        PMID: 19671788     DOI: 10.1177/0961203309106832

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  38 in total

Review 1.  Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis.

Authors:  Gabriela Cesarman-Maus; Carlos Cantú-Brito; Fernando Barinagarrementeria; Rosario Villa; Elba Reyes; Jorge Sanchez-Guerrero; Katherine A Hajjar; Ethel Garcia Latorre
Journal:  Stroke       Date:  2010-12-30       Impact factor: 7.914

3.  Chorea in primary antiphospholipid syndrome is associated with rheumatic fever.

Authors:  Simone Appenzeller; Steeven Yeh; Marcelo Maruyama; Solange Murta Barros; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2011-09-01       Impact factor: 2.631

Review 4.  The annexin A2 system and vascular homeostasis.

Authors:  Elle C Flood; Katherine A Hajjar
Journal:  Vascul Pharmacol       Date:  2011-03-29       Impact factor: 5.773

5.  Antiphospholipid syndrome: A disease of protean face.

Authors:  Mohammadreza Ardalan; Amir Vahedi
Journal:  J Nephropathol       Date:  2013-01-01

Review 6.  Antiphospholipid syndrome and the brain in pediatric and adult patients.

Authors:  E Muscal; R L Brey
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

Review 7.  Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease: JACC Scientific Expert Panel.

Authors:  Victor J Del Brutto; Seemant Chaturvedi; Hans-Christoph Diener; Jose G Romano; Ralph L Sacco
Journal:  J Am Coll Cardiol       Date:  2019-08-13       Impact factor: 24.094

8.  Pediatric APS: State of the Art.

Authors:  Arzu Soybilgic; Tadej Avcin
Journal:  Curr Rheumatol Rep       Date:  2020-03-03       Impact factor: 4.592

Review 9.  Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders.

Authors:  Saion Chatterjee; John D Pauling
Journal:  Clin Rheumatol       Date:  2020-09-21       Impact factor: 2.980

Review 10.  Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?

Authors:  Mohammad Hassan A Noureldine; Ali A Haydar; Ahmad Berjawi; Rody Elnawar; Ahmad Sweid; Munther A Khamashta; Graham R V Hughes; Imad Uthman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.